Inovio Pharmaceuticals, Inc.
INO
$1.34
$0.021.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 65.30K | 182.30K | 182.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 65.30K | 182.30K | 182.30K |
| Cost of Revenue | 48.49M | 52.19M | 54.21M | 56.83M | 62.23M |
| Gross Profit | -48.49M | -52.19M | -54.14M | -56.65M | -62.05M |
| SG&A Expenses | 30.77M | 31.54M | 32.68M | 33.07M | 33.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.26M | 83.72M | 86.89M | 89.90M | 96.03M |
| Operating Income | -79.26M | -83.72M | -86.82M | -89.72M | -95.85M |
| Income Before Tax | -67.43M | -84.93M | -84.95M | -108.09M | -87.76M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.43 | -84.93 | -84.95 | -108.09 | -87.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.43M | -84.93M | -84.95M | -108.09M | -87.76M |
| EBIT | -79.26M | -83.72M | -86.82M | -89.72M | -95.85M |
| EBITDA | -77.93M | -82.36M | -85.40M | -88.22M | -94.29M |
| EPS Basic | -1.17 | -1.70 | -1.93 | -2.63 | -2.66 |
| Normalized Basic EPS | -0.73 | -1.06 | -1.21 | -1.64 | -1.67 |
| EPS Diluted | -1.17 | -1.70 | -1.93 | -2.63 | -2.66 |
| Normalized Diluted EPS | -0.73 | -1.06 | -1.21 | -1.64 | -1.67 |
| Average Basic Shares Outstanding | 264.92M | 222.13M | 191.64M | 159.61M | 135.58M |
| Average Diluted Shares Outstanding | 264.92M | 222.13M | 191.64M | 159.61M | 135.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |